Cholera Vaccines Market to Grow at 9.32% CAGR through 2030
Increased
movement of people due to global travel also raises the risk of disease
transmission is expected to drive the Global Cholera Vaccines Market growth in
the forecast period, 2026-2030.
According to
TechSci Research report, “Cholera Vaccines Market – Global Industry Size,
Share, Trends, Competition, Forecast & Opportunities, 2020-2030F”,
the Global Cholera Vaccines Market stood at USD 97.32 Million in 2024 and is
expected to reach USD 166.50 Million by 2030 with a CAGR of 9.32% during the
forecast period.
The global
cholera vaccines market is experiencing significant growth driven by increasing
awareness of the need for preventive healthcare measures, the high burden of
cholera in endemic regions, and global efforts to control and eradicate the
disease. Cholera, an acute diarrheal infection caused by the Vibrio cholerae
bacteria, continues to pose a major public health threat, particularly in
low-income countries with poor sanitation and limited access to clean water.
The availability of vaccines has become a critical tool in reducing the
incidence of cholera and preventing outbreaks, contributing to the expanding
market for cholera vaccines worldwide.
The market is
primarily driven by oral cholera vaccines (OCVs), with leading products such as
Dukoral, Shanchol, and Euvichol dominating the landscape.
These vaccines have shown high efficacy in preventing cholera infection and are
particularly useful in settings with limited healthcare infrastructure. The
demand for cholera vaccines is especially high in countries located in regions
such as Asia Pacific, sub-Saharan Africa, and parts of South America, where
cholera remains endemic and where outbreaks are common. In these areas, cholera
can spread rapidly due to factors such as inadequate sanitation, overcrowding,
and contaminated water sources. The ability to distribute oral vaccines on a
large scale in these regions has made them an essential part of efforts to
control the disease.
The role of
international organizations such as the World Health Organization (WHO) and
GAVI, the Vaccine Alliance has been pivotal in driving vaccine accessibility
and availability in endemic regions. These organizations have provided funding,
supported large-scale vaccination campaigns, and facilitated the delivery of
vaccines to high-risk populations. For instance, WHO has endorsed the use of
oral cholera vaccines as part of its strategy for cholera control in countries
with recurrent outbreaks. As part of the Global Roadmap to Cholera Elimination
by 2030, the WHO has advocated for the increased use of OCVs in conjunction
with improvements in water, sanitation, and hygiene (WASH) infrastructure. Such
efforts have greatly contributed to the demand for cholera vaccines, as
countries seek to comply with international guidelines and goals for disease
prevention.
Despite the
advances in cholera vaccine development and distribution, challenges remain in
certain parts of the world. One of the most significant challenges is the
logistical difficulty of delivering vaccines to remote, hard-to-reach areas. In
many cholera-endemic regions, especially in sub-Saharan Africa and South Asia,
poor infrastructure, political instability, and natural disasters can disrupt
vaccination campaigns. Vaccines need to be stored and transported under
specific conditions, such as refrigeration, and any breakdown in the cold chain
can compromise their effectiveness. These logistical hurdles, combined with a
lack of sufficient healthcare resources and trained personnel, can hinder the
success of vaccination programs and limit their reach.
Another issue is
vaccine hesitancy, which can occur due to cultural beliefs, misconceptions
about vaccine safety, and a lack of understanding about the benefits of
vaccination. In certain communities, people may be reluctant to receive cholera
vaccines due to fears of side effects or a lack of trust in foreign health
interventions. Overcoming these barriers requires ongoing health education and
community engagement to increase vaccine acceptance. Campaigns to raise
awareness of the importance of cholera vaccination and its potential to save
lives are essential for ensuring higher vaccination coverage and controlling
the spread of the disease.
The global
cholera vaccines market is also influenced by economic factors, with vaccine
prices and funding availability playing a key role in market dynamics. While
cholera vaccines are generally affordable, the cost of large-scale vaccination
campaigns can be a significant burden for low-income countries with limited
healthcare budgets. Government spending, international aid, and partnerships
with private companies are crucial in making vaccines accessible to vulnerable
populations. The availability of financial support from organizations like GAVI
has helped reduce the financial burden on countries and facilitated the
expansion of vaccination coverage.
Innovation in
vaccine development continues to drive the market forward. Researchers are
exploring new formulations and approaches to improve the efficacy, safety, and
ease of administration of cholera vaccines. For example, new vaccines in
development may focus on improving the duration of protection or reducing the
number of doses required for effective immunity. Efforts to develop combination
vaccines that can protect against multiple infectious diseases, including
cholera, could further increase market demand by offering more comprehensive
immunization solutions.
The rise of
global tourism also plays a role in the growth of the cholera vaccines market.
As international travel increases, the risk of cholera spreading across borders
has also risen. Travelers to cholera-endemic regions are often recommended to
get vaccinated before their trips, further driving demand for cholera vaccines
in North America, Europe, and Australia. These regions may not have endemic
cholera, but they still experience a significant market for vaccines due to
travel and international health regulations.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Cholera Vaccines Market”
The Global Cholera
Vaccines Market is segmented into type, product, distribution channel, regional
distribution, and company.
Retail pharmacies are the fastest-growing segment in the cholera vaccine market, surpassing hospital pharmacies due to their wider access and higher distribution volume. Retail pharmacies serve a large portion of the population, particularly in urban and suburban areas, and are a key access point for preventive healthcare products, including vaccines. Their widespread reach and convenience make them essential in cholera vaccination campaigns, particularly in regions where healthcare infrastructure is limited.
In cholera-endemic areas, retail pharmacies have become a crucial point of contact for individuals seeking vaccination. They offer a more accessible, efficient, and convenient option, especially when healthcare facilities are overcrowded or under-resourced. Retail pharmacies, often working in collaboration with public health authorities, can distribute vaccines quickly during public health emergencies, providing an alternative to hospital-based vaccination.
Being part of larger healthcare networks and chains, retail pharmacies streamline vaccine distribution, ensuring proper storage and efficient delivery from rural to urban areas. Their collaboration with governments and organizations like the World Health Organization (WHO) has amplified their involvement in large-scale vaccination campaigns, making retail pharmacies an increasingly vital player in cholera vaccine distribution..
Based on region,
Africa is the second-largest region dominating the global cholera vaccines
market. This region has a particularly high demand for cholera vaccines due to
the recurring cholera outbreaks, widespread endemicity, and the challenges
posed by inadequate sanitation and limited access to clean water. In countries
like Haiti, Democratic Republic of Congo, Mozambique, Kenya, and Somalia,
cholera remains a significant public health threat, driving both government and
international health organizations to prioritize cholera prevention through
mass vaccination campaigns.
One of the
primary reasons for Africa’s prominence in the cholera vaccines market is the
high incidence of cholera outbreaks. According to the World Health Organization
(WHO), Africa remains one of the most affected continents in terms of cholera
cases. Cholera transmission is often facilitated by poor sanitation systems,
limited access to clean drinking water, and inadequate hygiene practices, all
of which are prevalent in many sub-Saharan African nations. For instance,
outbreaks in places like Haiti (though technically in the Caribbean, it has
connections to Africa’s cholera situation) and parts of East Africa are often
linked to poor infrastructure following natural disasters, flooding, and
population displacement, which increase the likelihood of cholera transmission.
The prevalence
of cholera in these areas has led to a significant focus on vaccination as a
key tool in outbreak prevention and control. Oral cholera vaccines (OCVs),
particularly Shanchol and Dukoral, have become essential in vaccination
campaigns across African countries. Shanchol is especially popular in this
region due to its affordability and broad serogroup coverage (against both O1
and O139 strains), which is critical as these two strains are responsible for
the majority of cholera outbreaks in Africa. The cost-effectiveness of Shanchol
makes it a viable solution in resource-constrained settings, where financial
limitations often pose challenges to healthcare delivery. The introduction of
these vaccines has significantly reduced the mortality rate associated with
cholera outbreaks, particularly in high-risk areas with frequent flooding,
inadequate sanitation, and large populations.
Major companies
operating in Global Cholera Vaccines Market are:
- Valneva SE
- Sanofi S.A.
- Emergent BioSolutions Inc.
- EuBiologics Co., Ltd.
- Shantha Biotechnics Limited
- Hilleman Laboratories Singapore Pte
Ltd
- Astellas Pharma Inc.
- Incepta Pharmaceuticals Ltd.
- Bharat Biotech Ltd.
- Takeda Pharmaceutical Company
Limited
Download FreeSample Report
Customers can
also request for 10% free customization on this report
“The future of
the global cholera vaccines market is poised for significant growth, driven by
increased vaccination efforts, heightened awareness, and advancements in
vaccine technology. As global health organizations like the WHO and GAVI
continue to prioritize cholera elimination, the demand for oral cholera
vaccines, particularly in endemic regions, is expected to rise. Innovative
vaccines with improved efficacy and longer-lasting protection, alongside more
efficient distribution channels, will further support market expansion. Growing
international support and funding for large-scale vaccination programs in
Africa, Asia, and other high-risk areas will contribute to widespread vaccine
access. With ongoing efforts to improve sanitation, the market is set to play a
crucial role in reducing cholera outbreaks globally, contributing to long-term
disease control and prevention.,” said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“Cholera Vaccines Market - Global Industry Size,
Share, Trends, Opportunity, and Forecast, Segmented By Type (Whole cell V.
Cholerae O1 Recombinant With B-Subunit and Killed Oral O1 & O139), By
Product (Vaxchora, Dukoral, Shanchol, and Others), By Distribution Channel
(Hospital Pharmacy, Retail Pharmacy and Others), By
Region and Competition, 2020-2030F”, has evaluated
the future growth potential of Global Cholera Vaccines Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Cholera Vaccines Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com